2024 STS Coronary Conference Submission Information

Important

• Visit sts.org to access the submission site.   
• All submissions should be related to surgery for coronary artery disease.  
• Accepted submissions will be presented as oral presentations or scientific posters. Authors must agree to abide by the Policy on STS Educational Activities for Presenters and Moderators.  
• Submitted abstracts must summarize an original contribution and must not have been presented, published, or accepted for presentation or publication elsewhere.  
• The STS Coronary Conference is excited to partner with the Society’s new open-access journal, Annals of Thoracic Surgery Short Reports, featuring research from the Coronary Conference. Benefits to authors submitting their STS Coronary Conference research to Annals Short Reports are as follows:   
  • Expedited peer review and online publication of accepted research   
  • Waived open-access Article Processing Charges for select articles, and/or 50% reduced fees for STS Members  
• Abstract authors may opt-in or opt-out of full manuscript submission to Annals of Thoracic Surgery Short Reports.  
• Planning Committee members will review abstracts, and authors will be notified of their decision by the middle of March 2024.  

Abstract Specifications  

• Use title case for your abstract title. Capitalize the first letter of each main word in the title; please do not enter information in all upper case or in quotation marks.  
• All abstracts must be structured using the following section headings:  
  • Purpose - Include a brief statement on the intent of the study and the current state of research in the field. Specifically, describe the quality gap (limitation or problem) within the practice of Coronary Surgery that the research addresses. (50-word maximum)
  • Methods - The methods of the study or experimental approach should be defined clearly and briefly. (100-word maximum) 
  • Results - Provide a summary of the study findings, including sufficient details to support the stated conclusions. These may be presented in a brief table (no more than five columns of data).  (150-word maximum)  
  • Conclusion - Include a statement concerning the significance of the work and its implications for further research. In what way might the results of this project supplement or inform clinical or research knowledge or strategies? (50-word maximum)  
• Identify the funding source for the research.  
• Tables: One (1) table is allowed.  
  • The table cannot have more than five (5) columns of data.  
  • The file should be in .jpg, .tif, or .png format. (PowerPoint images, Excel, and Word Documents are not permitted.)  
• Images: One (1) image is allowed.  
  • Images should be between 300 and 600 dpi at 3"x5".  
  • The file should be in .jpg, .tif, or .png format. (PowerPoint images, Excel, and Word Documents are not permitted)  
• Only abstracts submitted using the online system will be considered for presentation.  
• There should be no reference to the institutions involved in the body of the text.  
• Abstracts cannot contain product names; generic terms must be used when describing a product.  
• When percentages are used, the absolute numbers of derivation must be stated.  
• To ensure fairness, abstracts will be reviewed and graded in a blinded fashion with no references to authors or institutions. Abstracts are reviewed by peer reviewers based on scientific merit, originality, and practice gaps identified.  
• The submitting author must provide accurate email addresses of all coauthors and must attest that (a) all coauthors of the abstract have granted consent for the material to be submitted for presentation, and (b) that the submitting author has been granted the right by all coauthors to act on their behalf.  
• For the submitted abstract, each coauthor will be asked to complete a disclosure form.  
• STS reserves the right to withdraw any abstract at any time.  
• All abstracts must be submitted and presented in English.  
• If an abstract is not accepted as an oral presentation, it may be accepted as a scientific poster presentation instead. The final determination on format will be at the discretion of the Coronary Conference Course and Program Chairs and the Planning Committee.  
• The person listed as the presenting author for each abstract must register to attend the 2023 STS Coronary Conference. In the event that a change of presenting author must be made after the submission of the abstract, STS must be notified in writing. NOTE: The replacement presenter must be a coauthor of the abstract.  
• Once an abstract has been accepted, additional authors may not be added.  
• No abstract will be considered with deferred outcomes data. If data are to be presented, they must appear in the original abstract submitted. If there are any questions regarding changes in data after the abstract has been submitted, it is the responsibility of the presenting author to notify STS by email at STS Education Department.  
• Abstract content must be based upon the best available evidence and should not promote any health care device, drug, other product, or service.  
• If the presenter has any relationship posing a conflict or potential conflict relevant to his or her session, he or she may not make any recommendations regarding relevant products or services as part of that session.  
• If an abstract is selected, the authors will be asked to present it (a) orally during an abstract-based scientific session OR (b) at the poster session. Authors will receive complete information (including poster dimensions, setup times, etc.) after notification of the full Planning Committee’s decision.  
• To withdraw an abstract, the presenter must notify the STS in writing, by emailing the STS Education Department and including the title of the abstract. 

Disclosure Information

• Conflict of interest and FDA disclosure is required before an abstract will be accepted for consideration. If a potential conflict of interest exists, be sure to include the name of the organization/company and the nature of the potential conflict. Each author must submit her/his individual disclosure when completing the abstract submission.  
• It is the responsibility of the submitting author to identify each coauthor on the abstract. Upon submission of the abstract, an email will be sent to each coauthor, who will then be responsible for submitting her/his individual disclosure.  

For live presentations, all relationships with commercial interests and FDA disclosures, as defined in the STS Education Disclosure Policy, must be stated orally to the audience at the beginning of each presentation. In addition, a slide at the beginning of the PowerPoint presentation must be used to reveal the nature of the disclosure(s). This commercial relationship and FDA disclosure information will be noted in published materials. Speakers are required to communicate that they have nothing to disclose if that is the case.